ALK and non-small cell lung carcinoma: Based on these results, the US FDA, on May 21, 2017, approved the immunotherapy plus chemotherapy regimen, which involves pembrolizumab combined with carboplatin and pemetrexed for the treatment of patients with advanced non-squamous NSCLC not harboring EGFR/ALK mutations, independent of the expression of PD-L1.